These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
144 related articles for article (PubMed ID: 28340472)
1. Characterization of an unknown impurity in doxofylline using LC-MS and NMR. Zhu P; Lu J; Hong L; Su W; Van Schepdael A; Adams E J Pharm Biomed Anal; 2017 Jun; 140():31-37. PubMed ID: 28340472 [TBL] [Abstract][Full Text] [Related]
2. Identification and structural elucidation of an unknown impurity in carbamazepine active pharmaceutical ingredient by liquid chromatography-tandem mass spectrometry and semi-preparative chromatographic isolation. Thomas S; Mathela CS; Agarwal A; Paul SK J Pharm Biomed Anal; 2011 Sep; 56(2):423-8. PubMed ID: 21676571 [TBL] [Abstract][Full Text] [Related]
4. Characterization of a novel process-related impurity in commercial bendazac lysine eye drops by LC-ESI-QTOF/MS/MS and NMR. Zhu P; Yang W; Hong L; Cheng Q; Luo L; He J; Chen J J Pharm Biomed Anal; 2015 Mar; 107():437-43. PubMed ID: 25666544 [TBL] [Abstract][Full Text] [Related]
5. Isolation and characterization of a potential process related impurity of phenazopyridine HCl by preparative HPLC followed by MS-MS and 2D-NMR spectroscopy. Rao RN; Maurya PK; Raju AN J Pharm Biomed Anal; 2009 Jul; 49(5):1287-91. PubMed ID: 19376664 [TBL] [Abstract][Full Text] [Related]
6. Development and validation of a stability indicating assay of doxofylline by RP-HPLC: ESI-MS/MS, ¹H and ¹³C NMR spectroscopic characterization of degradation products and process related impurities. Rao RN; Naidu ChG; Prasad KG; Santhakumar B; Saida S J Pharm Biomed Anal; 2013 May; 78-79():92-9. PubMed ID: 23466440 [TBL] [Abstract][Full Text] [Related]
7. Isolation and identification of a major impurity in a new bulk drug candidate by preparative LC, ESI-MS(n), LC-MS-MS, and NMR. Li N; Yang J; Qin F; Li F; Gong P J Chromatogr Sci; 2007 Jan; 45(1):45-9. PubMed ID: 17254383 [TBL] [Abstract][Full Text] [Related]
8. Identification, characterization and quantification of a new impurity in deferasirox active pharmaceutical ingredient by LC-ESI-QT/MS/MS. Thomas S; Chandra Joshi S; Vir D; Agarwal A; Rao RD; Sridhar I; Xavier CM; Mathela CS J Pharm Biomed Anal; 2012 Apr; 63():112-9. PubMed ID: 22361658 [TBL] [Abstract][Full Text] [Related]
9. Isolation and characterization of novel degradation products of Doxofylline using HPLC, FTIR, LCMS and NMR. Raju CK; Pandey AK; S G; Ghosh K; Pola A; Goud P SK; Jaywant MA; Navalgund SG J Pharm Biomed Anal; 2017 Jun; 140():1-10. PubMed ID: 28334552 [TBL] [Abstract][Full Text] [Related]
10. Characterization of two unknown impurities in roxithromycin by 2D LC-QTOF/MS/MS and NMR. Wang J; Zhou J; Xu Y; Zhu B; Jin Y J Pharm Biomed Anal; 2020 May; 184():113196. PubMed ID: 32113121 [TBL] [Abstract][Full Text] [Related]
11. Characterization of unknown impurities in Coenzyme Q Deng Y; Chen X; Wang L; Peng X; Lin M J Pharm Biomed Anal; 2019 Oct; 175():112771. PubMed ID: 31330281 [TBL] [Abstract][Full Text] [Related]
12. Separation and structural characterization of unknown impurity in vancomycin by two-dimensional preparative liquid chromatography, LC-MS and NMR. Wang X; Qiu Y; Wen H; Weng R; Chen D; Liu H J Pharm Biomed Anal; 2023 Aug; 232():115403. PubMed ID: 37120972 [TBL] [Abstract][Full Text] [Related]
13. NMR and mass spectrometric characterization of vinblastine, vincristine and some new related impurities--part II. Háda V; Dubrovay Z; Lakó-Futó A; Galambos J; Gulyás Z; Aranyi A; Szántay C J Pharm Biomed Anal; 2013 Oct; 84():309-22. PubMed ID: 23177164 [TBL] [Abstract][Full Text] [Related]
14. Screening of synthetic PDE-5 inhibitors and their analogues as adulterants: analytical techniques and challenges. Patel DN; Li L; Kee CL; Ge X; Low MY; Koh HL J Pharm Biomed Anal; 2014 Jan; 87():176-90. PubMed ID: 23721687 [TBL] [Abstract][Full Text] [Related]
15. Characterization of a novel impurity in bulk drug eprosartan by ESI/MS(n) and NMR. Sun C; Wu J; Wang D; Pan Y J Pharm Biomed Anal; 2010 Feb; 51(3):778-83. PubMed ID: 19864105 [TBL] [Abstract][Full Text] [Related]
16. Development of a validated LC-MS/MS method for determination of doxofylline on rat dried blood spots and urine: application to pharmacokinetics. Rao RN; Prasad KG; Naidu ChG; Saida S; Agwane SB J Pharm Biomed Anal; 2013 May; 78-79():211-6. PubMed ID: 23501441 [TBL] [Abstract][Full Text] [Related]
17. The application of LC-NMR and LC-MS for the separation and rapid structure elucidation of an unknown impurity in 5-aminosalicylic acid. Novak P; Tepes P; Fistrić I; Bratos I; Gabelica V J Pharm Biomed Anal; 2006 Mar; 40(5):1268-72. PubMed ID: 16253464 [TBL] [Abstract][Full Text] [Related]
18. Development and validation of a sensitive LC-MS/MS method with electrospray ionization for quantitation of doxofylline in human serum: application to a clinical pharmacokinetic study. Sreenivas N; Narasu ML; Shankar BP; Mullangi R Biomed Chromatogr; 2008 Jun; 22(6):654-61. PubMed ID: 18254143 [TBL] [Abstract][Full Text] [Related]
19. Isolation and characterization of thermal degradation impurity in brimonidine tartrate by HPLC, LC-MS/MS, and 2DNMR. Baksam V; Nimmakayala S; Devineni SR; Muchumarri RMR; Shandilya S; Kumar P J Pharm Biomed Anal; 2021 Oct; 205():114297. PubMed ID: 34391137 [TBL] [Abstract][Full Text] [Related]
20. Semi-preparative isolation and structural elucidation of an impurity in citalopram by LC/MS/MS. Raman B; Sharma BA; Ghugare PD; Karmuse PP; Kumar A J Pharm Biomed Anal; 2009 Oct; 50(3):377-83. PubMed ID: 19556091 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]